Citrusin B

CAS No. 105279-10-5

Citrusin B( —— )

Catalog No. M31930 CAS No. 105279-10-5

Citrusin B exhibits moderate in vitro inhibitory effect on tobacco mosaic virus replication with IC50 values 0.26 mmol L 1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 603 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Citrusin B
  • Note
    Research use only, not for human use.
  • Brief Description
    Citrusin B exhibits moderate in vitro inhibitory effect on tobacco mosaic virus replication with IC50 values 0.26 mmol L 1.
  • Description
    Citrusin B exhibits moderate in vitro inhibitory effect on tobacco mosaic virus replication with IC50 values 0.26 mmol L 1.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    105279-10-5
  • Formula Weight
    568.6
  • Molecular Formula
    C27H36O13
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Leonloside D

    Leonloside D is a natural product.

  • Rhamnocitrin 3-apios...

    Rhamnocitrin 3-apiosyl-(1a??2)-glucoside is a natural product for research related to life sciences.

  • 20-Hydroxylucidenic ...

    20-Hydroxylucidenic acid E2 is a triterpenoid compound found in Ganoderma lucidum. It exhibits significant inhibitory effects on inflammation induced by TPA . Additionally, 20-Hydroxylucidenic acid E2 can suppress the expression of EBV early antigen induced by TPA , with a IC50 of 290 mol ratio/32 pmol TPA (meaning that when the molar concentration of this compound is 290 times that of 32 pmol of TPA, it can inhibit 50% of EBV early antigen expression). Therefore, 20-Hydroxylucidenic acid E2 has potential applications in anti-inflammatory and anticancer research.